The Importance of a Checkpoint Inhibitor in Immunotherapy

The phyoneo antigen cancer vaccine space is sort of increasingly taking the view that that might be where this approach might have the most success. And they're doing something which we've captured in prior analyses they're kind of pointing this in the direction of settings of low tumor burden so a resected tumor setting or an early stage setting. The combination of broad immune activation through a checkpoint inhibitor, and then specific activation of an individual patients immune responses against their specific tumor could hit that sweet spot for immuno oncology mechanisms.